Bristol Myers Valuation
| BMY Stock | MXN 1,222 16.45 1.36% |
At this time, the firm appears to be overvalued. Bristol Myers Squibb shows a prevailing Real Value of 1104.18 per share. The current price of the firm is 1222.0. Our model approximates the value of Bristol Myers Squibb from analyzing the firm fundamentals such as Return On Equity of 0.18, profit margin of 0.14 %, and Current Valuation of 3.9 T as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Bristol Myers' price fluctuation is very steady at this time. Calculation of the real value of Bristol Myers Squibb is based on 3 months time horizon. Increasing Bristol Myers' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Bristol Myers is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Bristol Stock. However, Bristol Myers' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1222.0 | Real 1104.18 | Hype 1222.0 | Naive 1182.31 |
The intrinsic value of Bristol Myers' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Bristol Myers' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Bristol Myers Squibb helps investors to forecast how Bristol stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Bristol Myers more accurately as focusing exclusively on Bristol Myers' fundamentals will not take into account other important factors: Bristol Myers Total Value Analysis
Bristol Myers Squibb is currently anticipated to have takeover price of 3.9 T with market capitalization of 2.87 T, debt of 39.6 B, and cash on hands of 29.36 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Bristol Myers fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
3.9 T | 2.87 T | 39.6 B | 29.36 B |
Bristol Myers Investor Information
About 79.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 2.41. Bristol Myers Squibb recorded earning per share (EPS) of 55.43. The entity last dividend was issued on the 5th of January 2023. Based on the key indicators related to Bristol Myers' liquidity, profitability, solvency, and operating efficiency, Bristol Myers Squibb is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Bristol Myers Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Bristol Myers has an asset utilization ratio of 42.23 percent. This suggests that the Company is making 0.42 for each dollar of assets. An increasing asset utilization means that Bristol Myers Squibb is more efficient with each dollar of assets it utilizes for everyday operations.Bristol Myers Ownership Allocation
Bristol Myers holds a total of 2.13 Billion outstanding shares. The majority of Bristol Myers Squibb outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Bristol Myers Squibb to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Bristol Myers. Please pay attention to any change in the institutional holdings of Bristol Myers Squibb as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Bristol Myers Profitability Analysis
The company reported the revenue of 46.16 B. Net Income was 6.33 B with profit before overhead, payroll, taxes, and interest of 36.02 B.About Bristol Myers Valuation
Our relative valuation model uses a comparative analysis of Bristol Myers. We calculate exposure to Bristol Myers's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Bristol Myers's related companies.Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. BRISTOL MYERS operates under Drug Manufacturers - Major classification in Mexico and is traded on Mexico Stock Exchange. It employs 23300 people.
8 Steps to conduct Bristol Myers' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Bristol Myers' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Bristol Myers' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Bristol Myers' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Bristol Myers' revenue streams: Identify Bristol Myers' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Bristol Myers' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Bristol Myers' growth potential: Evaluate Bristol Myers' management, business model, and growth potential.
- Determine Bristol Myers' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Bristol Myers' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Bristol Stock Analysis
When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.